The APOBEC3 (A3) genes encode cytidine deaminase proteins with potent antiviral and anti-retroelement activity. This locus is characterized by duplication, recombination, and deletion events that gave rise to the seven A3s found in primates. These include three single deaminase domain A3s (A3A, A3C, and A3H) and four double deaminase domain A3s (A3B, A3D, A3F, and A3G). The most potent of the A3 proteins against HIV-1 is A3G. However, it is not clear if double deaminase domain A3s have a generalized functional advantage to restrict HIV-1. In order to test whether superior restriction factors could be created by genetically linking single A3 domains into synthetic double domains, we linked A3C and A3H single domains in novel combinations. We found that A3C/A3H double domains acquired enhanced antiviral activity that is at least as potent, if not better than, A3G. Although these synthetic double domain A3s package into budding virions more efficiently than their respective single domains, this does not fully explain their gain of antiviral potency. The antiviral activity is conferred both by cytidine-deaminase dependent and independent mechanisms, with the latter correlating to an increase in RNA binding affinity. T cell lines expressing this A3C-A3H super restriction factor are able to control replicating HIV-1ΔVif infection to similar levels as A3G. Together, these data show that novel combinations of A3 domains are capable of gaining potent antiviral activity to levels similar to the most potent genome-encoded A3s, via a primarily non-catalytic mechanism.
Antiviral genes are encoded by all organisms to help protect them from viral infections, including proteins encoded by primates to protect them from viruses similar to HIV-1. These antiviral proteins are also called “restriction factors”. Some restriction factors are broadly acting, while others are very specific. During the course of evolution, some of these genes have expanded into multiple copies and rearranged in different versions to give them new activities. In this paper, we validated the hypothesis that one particular antiviral gene family, called the APOBEC3 family, has the capability of making novel combinations of antiviral human genes with as great, or greater, potency against HIV-1 as the most potent natural member of this family. By combining parts of the APOBEC3 proteins into novel combinations, we created potent antiviral versions that act through a mechanism distinct from existing APOBEC3 proteins.
Citation: McDonnell MM, Karvonen SC, Gaba A, Flath B, Chelico L, Emerman M (2021) Highly-potent, synthetic APOBEC3s restrict HIV-1 through deamination-independent mechanisms. PLoS Pathog 17(6): e1009523. https://doi.org/10.1371/journal.ppat.1009523
Editor: Welkin E. Johnson, Boston College, UNITED STATES
Received: March 31, 2021; Accepted: June 7, 2021; Published: June 25, 2021
Copyright: © 2021 McDonnell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The sequencing reads were uploaded to the NCBI SRA with BioProject accession number PRJNA643546 and PRJNA718082 The computational pipeline used to analyze the sequencing data and generate are available on GitHub (https://github.com/molliemcdonnell/SuperRestrictionFactor_Hypermutation2).
Funding: This work was supported by a National Science Foundation predoctoral fellowship (NSF DGE-1762114) to M.M.M., National Institutes of Health P50AI150476 (principal investigator [PI], Nevan Krogan; subaward to M.E.), National Institutes of Health R01 AI030927 to M.E., and Canadian Institutes of Health Research grant PJT-162407 to L.C., and a Saskatchewan Health Research Foundation postdoctoral fellowship to A.G. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Positive selection in host antiviral genes is a result of the host-virus “arms-race” due to repeated cycles of host resistance and virus adaptation . These cycles of mutation-selection that increase the evolutionary rate of single amino acid substitutions are characteristic of many host genes that counteract HIV and related lentiviruses [1,2]. Additional innovation in host antiviral genes also occurs through gene duplication and recombination creating antiviral gene families that, through neo- or sub-functionalization, is an attractive evolutionary strategy to expand host anti-pathogen response. For example, most mammals, including humans, encode two paralogs of Mx proteins, MxA and MxB. Human MxA has broad and potent activity against a diverse range of RNA and DNA viruses, while the antiviral scope of human MxB is more limited to lentiviruses and herpesviruses [3–6]. Additionally, TRIM5, a potent restriction factor against lentiviruses, is present in only a single copy in most primates, whereas rodents have up to six .
Antiviral gene family expansion is also seen within the apolipoprotein B mRNA editing enzyme catalytic-polypeptide like 3, APOBEC3 (shortened to A3 here) locus. A3s are a family of cytidine deaminases that hypermutate retroviruses, such as HIV-1, as well as endogenous retroelements. The APOBEC3 (A3) locus, which is unique to placental mammals, has undergone dramatic expansion in many mammalian lineages, including primates. For example, the human genome encodes seven A3 paralogs (named A3A, A3B, A3C, A3D, A3F, A3G, and A3H). In the majority of placental mammals, the A3 loci is flanked by CBX6 and CBX7 genes, suggesting that the amplification of A3 genes has mainly occurred via tandem gene duplication within the locus [8–12]. In addition to this gene duplication, most of the A3 proteins are rapidly evolving in primates, suggesting that each has evolved to counteract pathogens [9,13].
The A3 gene family encodes a characteristic zinc-coordinating catalytic motif (His-X-Glu-X23-28-Pro-Cys-X2-4-Cys) which can be grouped into 3 classes (A3Z1, A3Z2, and A3Z3) on the basis of their conserved Z domain sequences. Of the seven A3 paralogs in humans, A3A, A3C, and A3H encode single domain proteins (A3Z1, A3Z2, and A3Z3, respectively), whereas the four remaining A3s are double Z domains. A3B and A3G are categorized as A3Z2-A3Z1, while A3D and A3F are A3Z2-A3Z2 [9,10,12]. The human A3 proteins also vary in their ability to restrict HIV-1. Human A3A and A3B do not have antiviral activity against HIV-1, while human A3G is the most potent naturally found A3 against HIV-1 and other retroviruses .
The human A3 locus has also diversified through polymorphisms that encode proteins with different antiviral activities. For example, the common form of A3C encodes a serine at position 188 and weakly inhibits HIV-1, but a natural variant that encodes for an isoleucine at position 188 has greater antiviral activity . Additionally, A3H has over four major haplotypes circulating in the human population with varying ability to restrict HIV-1 [16–18]. Because of the potent antiviral restriction these A3s pose, lentiviruses, including HIV-1, have evolved to encode an antagonist, Vif, that abrogates restriction by inducing A3 degradation. Strain-dependent mutations in Vif affect its ability to degrade different A3H variants, indicating that viral polymorphisms also affect A3 activity [19,20].
Despite the A3 gene variation in their potency, domain composition, and susceptibility to antagonism by Vif, there are combinations of human A3 proteins that remain unsampled. For example, not all of the double Z domain combinations have been sampled in primates, and many combinations of A3 double domains with polymorphisms are unsampled . We predicted that novel double domain combinations may prove to be more effective inhibitors of HIV-1 and we refer to these kinds of evolutionary-based variants of natural antiviral proteins with improved potency and/or escape from antagonism as “super restriction factors” [21–23]. Our previous study showed that duplicating the single A3Z2 domain protein A3C created an A3C-A3C tandem domain protein with increased antiviral activity relative to its single domain counterpart that was also largely resistant to degradation by HIV-1 Vif . Nonetheless, the gain of antiviral potency of A3C-A3C is relatively modest and not as potent as A3G, which is the most potent human A3 protein so far described against HIV-1.
In this study, we created novel human A3 proteins by combining the single domain A3C with the single domain A3H in different orientations and with different natural polymorphisms and show that these A3C/A3H double domains are at least as potent inhibitors of HIV-1 as A3G. A3C/A3H double domains are packaged into virions more efficiently than their single domain counterparts, but do not have an increase in hypermutation activity relative to their single domain counterparts. Rather, they have gained potent antiviral activities independent of cytidine deamination and have gained stronger affinity for binding RNA. Creation of T cell lines that stably express an A3C/A3H double domain show that A3C-A3H restricts spreading infection of HIV-1ΔVif as well as A3G, albeit again, by a different antiviral mechanism. These studies show that by exploring evolutionary space of the APOBEC3 locus in humans, novel combinations of poorly active antiviral A3 proteins can be created that are as potent as the most active A3 proteins.
A3C/A3H chimeras are at least as potent as A3G
Each of the human A3s is comprised of either one or two of these conserved zinc-coordinating domains: A3Z1, A3Z2, or A3Z3 (Fig 1A). A3H is unique because it is the only A3 with a Z3 domain. Furthermore, in mammals this Z3 domain has been duplicated only in Carnivora, where it subsequently acquired premature stop codons  and has not recombined to make a Z3-containing double domain A3 in any primate genome . However, a splice variant makes a Z2-Z3 fusion protein with antiviral activity in felines has been reported . Therefore, in order to explore the evolutionary potential of novel human A3 combinations, we created synthetic tandem domain proteins consisting of one Z2 and one Z3 domain together in a single protein. These synthetic Z2-Z3 and Z3-Z2 proteins consist of A3H and the common variant of A3CS188 domains (Fig 1A). A previous study showed that a human A3C-A3H combination had antiviral activity , but here we also used two variants of A3H: haplotype I (hap I), the less stable and less antiviral A3H protein, and haplotype II (hap II), the more stable and more antiviral A3H protein [17,18] (Fig 1A), as well as tested the orientation of the A3 domains in both directions, i.e. both A3C-A3H and A3H-A3C. In addition, the linker between the two domains in our proteins is different, as we designed the Z2/Z3 and Z3/Z2 double domains based on alignments to naturally found double A3Z2 domains, A3D and A3F, and incorporated the short linker sequence between both domains (Arg-Asn-Pro) found in A3D and A3F  (see S1 Fig for sequence annotation). These designed Z2/Z3 and Z3/Z2 double domain A3s are analogous to natural Z2-Z1 and Z2-Z2 combinations that have not yet been naturally sampled in primate lineages.
(A) Cartoon schematic the A3 gene locus and of the A3C/A3H double domains synthesized. The Z1 domains are labeled in green, the Z2 domains in purple, and the Z3 domains in blue (light blue for A3Hhap I and dark blue for A3Hhap II). The synthetic double domains, A3C-A3H and A3H-A3C are Z2/Z3 and Z3/Z2, respectively. All double domains used in these experiments have a C-terminal 3XFLAG epitope tag. (B) Top: Single-cycle infectivity assay measuring the percent infectivity of each A3 variant against HIV-1ΔEnvΔVif normalized to transfections in the absence of A3. Cells were transfected with 100ng of A3 and 600ng of HIV-1ΔEnvΔVif pseudotyped with 100ng of VSV-g. Virus production was quantified by an RT assay (see Methods) and equal amounts of virus was used to infect SUPT1 cells. The bar graph shows an average of 3 biological replicates, each with triplicate infections (+/- SEM). Statistical differences were determined by unpaired t tests: ** P≤0.01, ns = not significant. Bottom: Representative western blot of the intracellular levels of A3 in 293Ts. Antibodies to FLAG were used to detect A3s and actin was used as a loading control. (C) Top: The % infectivity of HIV-1ΔEnvΔVif pseudotyped with VSV-g and increasing doses of transfected A3G (grey), A3C-A3Hhap II (dark blue), or A3Hhap II-A3C (light blue) are plotted, normalized to a control with no A3. The amount of each A3 plasmid transfected in ng is shown on the X-axis. Data points are an average of 3 biological replicates, with each biological replicate consisting of 3 triplicate infections (+/- SEM). Statistical differences were determined by unpaired t tests between A3G and A3C-A3Hhap II and A3G and A3Hhap II-A3C: * P ≤ 0.05, ns = not significant. Bottom: Western blot showing the intracellular expression levels of A3G, A3C-A3Hhap II, and A3Hhap II-A3C probed with anti-FLAG antibody showing intracellular expression levels for A3s and actin as a loading control. The ng of A3 transfected are denoted on top of the western blot.
In order to test the antiviral activity of these proteins, we performed single-cycle infectivity assays by transfecting 293T cells with an expression vector encoding these synthetic genes along with an HIV-1 provirus lacking the A3 antagonist Vif. A3G was used as a positive control, as it is the most potent human A3. A3G can restrict HIV-1ΔEnvΔVif infection by over two orders of magnitude (Fig 1B top). As previously described [17,18], A3Hhap I weakly inhibits HIV-1ΔEnvΔVif, and A3Hhap II more potently inhibits HIV-1ΔEnvΔVif, though not as strongly as A3G despite similar expression levels (Fig 1B). A3C also weakly inhibits HIV-1ΔEnvΔVif, but as we previously reported, the antiviral activity of A3C can be increased several fold by creating a synthetic tandem domain, A3C-A3C . Nonetheless, A3C-A3C is still less antiviral than A3G at similar expression levels. In contrast, we found that A3C-A3Hhap I and A3Hhap I-A3C synthetic tandem domain proteins were as potent A3G (Fig 1B top). Thus, remarkably, two A3 single domain proteins that on their own have little antiviral activity, can produce a synthetic double domain protein with the ability to restrict HIV-1ΔEnvΔVif by two orders of magnitude.
Moreover, when combining A3C with the more active A3H haplotype, A3Hhap II, to create A3C-A3Hhap II and A3Hhap II-A3C, we could make antiviral proteins that are 9-fold and 11-fold, respectively, more active against HIV-1ΔEnvΔVif than A3G (Fig 1B top). This increase in antiviral activity could not be explained by increased expression levels since A3C and A3Hhap II single domain proteins are expressed to similar levels as A3C-A3Hhap II and A3Hhap II-A3C (Fig 1B bottom). Additionally, A3C-A3Hhap II and A3Hhap II-A3C are expressed to the same level as A3G (Fig 1B bottom).
To more thoroughly examine whether activity is correlated with expression level, we transfected different amounts of plasmids encoding these synthetic tandem domain proteins along with A3G. A3G could restrict HIV-1ΔEnvΔVif approximately 3-fold even at the lowest level of DNA transfected (10ng). However, both A3C-A3Hhap II and A3HhapII-A3C were able to restrict HIV-1ΔEnvΔVif more potently than A3G at every dose tested (Fig 1C). Even at the lowest dose of 10ng with low protein level expression, both A3C-A3Hhap II and A3HhapII-A3C were able to inhibit HIV-1ΔEnvΔVif approximately 30- and 70- fold, respectively. In summary, by creating novel double domains from poorly-restrictive single domain A3s, we can create a super restriction factor that is at least as potent than A3G even at the lowest end of protein expression.
A3C/A3H chimeras are packaged better than their single domain counterparts
Previous studies have found a direct correlation of increase in packaging to potency of A3s [14,25]. Therefore, we evaluated the packaging of A3C/A3Hhap II double domains to get packaged into virions. We focused the experiments on A3C-A3Hhap II and A3Hhap II-A3C (hereafter referred to as A3C-A3H and A3H-A3C) double domains as they were the most potent combination in our assays (Fig 1). The intracellular expression levels of the naturally found A3s, A3G, A3Hhap II, and A3C, are all similar to A3C-A3H and A3H-A3C (Fig 2A top). Both A3C and A3Hhap II single domain proteins are poorly incorporated into virions (Fig 2A bottom). As we previously reported , the double domain A3C-A3C is packaged 3.3-fold more than A3C and A3G 2.0-fold more than A3C (Fig 2 bottom and quantified from three independent replicates in 2B). Here, we found that A3C/A3H double domains also have an increase in packaging relative to their single domain counterparts; A3C-A3H is packaged 4.6-fold more than A3C and A3H-A3C is packaged 9.0-fold more than A3C (Fig 2 bottom and quantified from three independent replicates in 2B). However, the increase in packaging of A3C/A3H alone is unlikely to explain all of the 650-fold increase in antiviral activity between A3C and A3C/A3H double domains since A3C-A3C is also packaged at similar levels but is not nearly as potent an antiviral protein. Furthermore, the packaging of A3H-A3C is more variable despite still potently restricting HIV-1ΔEnvΔVif in infectivity assays, suggesting that the increase in packaging alone does not completely explain the increase in antiviral activity (Figs 2B and 1B).
(A) Intracellular expression and packaging of A3 into virions. HIV-1ΔEnvΔVif provirus was co-transfected into 293T cells with 100ng of each A3. Top: western blot of cellular lysates probed with anti-FLAG antibody showing intracellular expression levels for A3s and actin as a loading control. Bottom: Western blot of proteins in the pelleted virions and probed with anti-FLAG antibody for A3 levels and anti-p24gag for normalization. An empty vector condition was used as a negative control and labeled no A3. A3C-A3Hhap II is shortened to A3C-A3H and A3Hhap II-A3C is shortened A3H-A3C. Western blot shown is representative of 3 biological replicates. (B) Quantification of the amount of A3 packaged relative to A3C from three biological replicate transfections. A3 packaged was calculated by dividing the abundance of A3 in the virions normalized to p24gag by the level of A3 expression in the cell normalized to actin. The amount of A3 packaged is reported relative to A3C, whose level was set to a value of 1 and denoted with the dotted line. Error bars represent the SEM. Statistical differences were determined by unpaired t tests between A3C and A3G, A3C and A3C-A3Hhap II, A3C and A3H, and A3C and A3Hhap II-A3C: * P ≤ 0.05, ** P ≤ 0.01, and ns = not significant.
A3C/A3H chimeras have gained a deaminase-independent mechanism to inhibit HIV that correlates with inhibition of reverse transcription (RT) products and increased affinity for RNA
Naturally found A3 proteins primarily use deaminase-dependent mechanisms to inhibit HIV-1 by converting cytidines to uracils on ssDNA in the minus strand of DNA during reverse transcription, leading to G-to-A mutations in the positive strand of proviral DNA . A3G has been documented to induce hypermutation of up to 10% of guanosine residues in the HIV-1 genome . Mutating the active sites in A3G mostly, but not completely, abrogates the antiviral activity, demonstrating the primary uses of deaminase-dependent methods of hypermutation to inhibit HIV-1 replication, although a deaminase-independent mechanism of viral inhibition is still detected [28,29]. Previously, we found that A3C-A3C double domain proteins did not increase the amount of G-to-A mutations in HIV-1 in a single-cycle infectivity assay, but rather increased their antiviral activity through inhibition of reverse transcription .
To test whether or not the large increase in antiviral activity of A3C/A3H double domains can be explained by an increase in hypermutation, we analyzed HIV-1 hypermutation induced by each A3C/A3H double domain using a recently described method to deep sequence all G-to-A mutations induced by a given A3 over a region of HIV-1 pol . A “plasmid control” was used to identify PCR- and Illumina-induced errors while the “No A3” condition controlled for mutations that arise during reverse transcription (Fig 3A). Consistent with previous results , we found that A3G induces more than 1 mutation in over 96% of the reads and more than 10 mutations in over 43% of the reads. In contrast, A3C induced far fewer reads with G-to-A mutations, with only 12% of the reads having 2 or more mutations. As previously reported , A3C-A3C induces similar frequencies of G-to-A mutations as A3C. A3Hhap II induced at least one G-to-A mutation in more than half of all reads and 10 or more mutations in approximately 10% of the reads, demonstrating significant hypermutation, but less than A3G. In contrast, despite the 500-fold increase in antiviral activity of A3C-A3H and A3H-A3C compared to A3Hhap II, we found no increase in hypermutation of A3C-A3H and A3H-A3C relative to A3Hhap II (Fig 3A compare distribution of mutations in right box on the top row with the distribution of mutations in the last right most boxes on the bottom row). A3H-A3C induces at least one mutation in approximately 30% of reads, similar to A3C-A3C or A3C alone. A3C-A3H induces at least one G-to-A mutation in 55% of the reads and 2 or more mutations in 38% of all reads, similar to the level of A3HhapII-mediated hypermutation. The low levels of hypermutation for these potent antiviral double domain proteins suggests a hypermutation-independent mechanism for super restriction.
(A) Paired-end sequencing reads were analyzed for G-to-A mutations. Data is shown as frequency distribution bar graphs of the percent of reads by the number of G-to-A substitutions in each read for each A3 tested. Plasmid control (referred to as plasmid ctrl) was used as a sequencing control and a no A3 sample was used to distinguish background mutations, including reverse transcriptase-induced mutations. A3C-A3Hhap II is shortened to A3C-A3H and A3Hhap II-A3C is shortened A3H-A3C. (B) Single-cycle infectivity assay measuring the percent infectivity of each A3 variant against HIV-1ΔEnvΔVif. Catalytic knockouts of the essential glutamic acid in both N- and C- terminal domains of A3C-A3Hhap II and A3Hhap II-A3C (shortened to cat KO) were created and compared to their catalytically active counterpart. Cells are transfected with 100ng of A3 and 600ng of HIV-1ΔEnvΔVif pseudotyped with 100ng of VSV-g. Virus production was normalized and equal amounts of virus was used to infect SUPT1 cells. Results from each experiment were normalized to a no A3 control. Bar graph shows an average of 3 biological replicates, each with triplicate infections (+/- SEM). Statistical differences were determined by unpaired t tests: ns = not significant. (C) To evaluate the relative copies of late reverse transcription products, SUPT1 cells were infected with HIV-1ΔEnvΔVif and either no A3 or 100ng of A3 to test for inhibition of HIV-1 reverse transcriptase products. 18 hours later, viral cDNA was harvested and the levels of HIV-1 proviral DNA was assayed by qPCR. Each circle represents a normalized value for the respective biological replicate, with qPCR technical duplicates. A3C-A3Hhap II is shortened to A3C-A3H and A3Hhap II-A3C is shortened A3H-A3C. Each sample has been adjusted for equal viral infection and a nevirapine control. Bars represent the mean across 3 biological replicates.
In order to complement the A3-mediated hypermutation analysis, we also made catalytically inactive A3C/A3H proteins by mutating the glutamic acid essential for the deamination reaction in both domains of the double domain proteins. We found that restriction by the catalytically inactive version of A3C-A3H, A3C-A3H E60A E240A, called A3C-A3H cat KO, was indistinguishable from the unmutated A3C-A3H (0.12% infectivity versus 0.08% infectivity (Fig 3B). This suggests that A3C-A3H primarily uses cytidine deaminase-independent mechanism of restriction, supporting the conclusions from the hypermutation data. Interestingly, in A3H-A3C when both active sites have been mutated to an alanine, A3H-A3C E57A E247A (here called A3H-A3C cat KO), can only inhibit HIV-1ΔEnvΔVif to 0.39% (compared to 0.15% infectivity with wild-type A3H-A3C), suggesting that A3H-A3C also uses both a deaminase-dependent and a deaminase-independent mechanism to restrict HIV-1 (Fig 3B). Thus, these data support a model that novel combinations of A3 domains have created super restriction factors that potently inhibit HIV-1ΔEnvΔVif predominantly through a deaminase-independent mechanism.
We also quantified the amount of late RT products in the presence of synthetic A3s. Unintegrated DNA was harvested 18 hours after infection and quantified by qPCR, normalized to the amount of virus used for each infection. As previously reported [29–31], virus produced in the presence of A3G showed a significant decrease in relative late RT products compared to the no A3 control (Fig 3C). On the other hand, virus produced in the presence of A3Hhap II or A3C had similar levels of late RT products as the no A3 control. Strikingly, virus made in the presence of A3C-A3H or A3H-A3C accumulated even fewer late RT products than in the presence of A3G (Fig 3C), mirroring the difference in antiviral activity (Fig 1B). These results suggest that inhibition of the formation of reverse transcriptase products is likely the major mechanism by which the A3C/A3H double domain proteins act and accounts for their greater antiviral activity relative to A3G. These findings support the hypothesis that A3C/A3H super restriction factors function in a novel deaminase-independent mechanism compared to their single domain counterparts.
One possible mechanism for reduced reverse transcriptase products in the presence of A3C-A3H would involve steric hinderance of reverse transcriptase due to competition between the A3 and reverse transcriptase for the template RNA. An increase in affinity for binding to RNA by A3C-A3H is an attractive possibility as A3H has previously been shown to bind RNA [32–35]. To determine the ability of the different A3s to interact with HIV-1 RNA, we conducted steady-state rotational anisotropy with fluorescein labeled HIV 5’UTR RNA and increasing amount of A3. The anisotropy can rise or decrease upon interaction of the binding partners, with a rise indicating a simple interaction and a decrease indicating an interaction and structural change of the 5’UTR [36,37]. The resulting saturation curves were analyzed to determine the dissociation constant (Kd), where a lower Kd value indicates less dissociation and tighter binding. We chose to compare A3C-A3H to A3Hhap II, as previous results found that A3C does not package into virions by binding RNA and does not form RNA mediated multimers in cells, in contrast to A3H [25,34,38]. We found that all the A3s examined decreased the anisotropy of the 5’UTR, suggesting that they were able to change the RNA structure (Fig 4). A3C-A3H bound RNA with a Kd of 0.03 nM, 17-fold stronger than A3Hhap II (Kd = 0.52 nM), consistent with its increase ability to inhibit RT products (Fig 4). A3G exhibited a much lower affinity for the 5’UTR, with a Kd of 6.36 nM. This is consistent with A3G inhibiting RT at least in part by binding to reverse transcriptase directly . These data support the model that increased affinity for RNA is responsible for an inhibition of RT products in the presence of A3C-A3H as a deaminase-independent mechanism of HIV antiviral activity.
The apparent Kd of A3 enzymes from the fluorescein labeled 497 nt RNA was analyzed by steady-state rotational anisotropy for (A) A3C-A3Hhap II (0.03 ± 0.01 nM); (B) A3Hhap II (0.52 ± 0.18 nM) and (C) A3G (6.36 ± 3.18 nM). The x-axis on each graph is different due to the different amount of protein added in order to fully saturate the RNA. Error bars represent the standard deviation from three independent experiments.
Stable expression of A3C-A3H in T cells inhibits HIV-1 replication in a Vif-dependent manner
All the previous experiments were done as single-cycle infectivity assays after co-transfection of A3 proteins with a provirus to determine antiviral activity. To more closely mimic natural infection, we next tested whether these super restriction factors could also inhibit spreading infections of HIV when stably expressed in a T cell line. We integrated the A3C-A3H gene into Jurkat T cells using the Sleeping Beauty transposon, which should integrate a single copy of A3C-A3H into the T cell genome . As controls, we also created similar cell lines that express A3G or an empty vector. A3G and A3C-A3H were expressed at similar levels in these lines, as assessed by western blot (Fig 5A).
(A) Western blot of the Jurkat cells constitutively expressing no A3, A3G, or A3C-A3Hhap II (shortened to A3C-A3H) probed with anti-FLAG for the A3 levels and actin as a loading control. (B) Spreading infection kinetics of a replication-competent HIV-1 with a deletion that spans the Vif open reading frame (called HIV-1ΔVif). The Jurkat cells expressing no A3 (circles, grey line), A3G (squares, green line), or A3C-A3Hhap II (shortened to A3C-A3H, triangles, purple line) were infected at a low MOI (MOI = 0.01) in triplicates. Virus production was monitored over time by collecting supernatant and measuring RT activity (mU/mL) using a SG-PERT assay. Error bars represent the standard error across the 3 biological replicates. To compare spreading infection kinetics, area under the curve (AUC) was calculated for each biological replicate. The mean AUC and standard error of the mean are represented to the right. (C) A3 mediated hypermutation analysis of gDNA from cells harvested on day 14. Paired-end sequencing reads were analyzed for G-to-A mutations. Data is shown as frequency distribution bar graphs of the percent of reads by the number of G-to-A substitutions in each read for each A3 tested. Plasmid control was used as a sequencing control and a no A3 sample was used to distinguish mutations that occurred throughout the 14-day time course. Frequencies are calculated as the average frequency of each biological infection replicates and read counts are shown as the sum of the reads for each replicate. (D) Spreading infection kinetics of a replication-competent wtHIV-1 (LAI isolate). Jurkat cells expressing no A3 (circles, grey line), A3G (squares, green line), and A3C-A3Hhap II (shortened to A3C-A3H, triangles, purple line) were infected in triplicate at a low MOI (MOI = 0.01). Virus production was monitored over time by collecting supernatant and measuring RT activity (mU/mL) using a SG-PERT assay. Error bars represent the standard error across the 3 biological replicates. To compare spreading infection kinetics, area under the curve (AUC) was calculated for each biological replicate. The mean AUC and standard error of the mean are represented to the right. (E) Western blot of cell lysates collected on day 14 from HIV-1ΔVif infection (B), shortened to ΔVif, and from wtHIV-1 infection (D), shortened to wt. Cells expressing A3G or A3C-A3Hhap II were evaluated for their intracellular expression levels of A3 in each of the triplicate infections. The anti-FLAG antibody was used to probe for the FLAG tagged A3s and actin was used as a loading control.
Jurkat cells expressing empty vector (no A3), A3G, or A3C-A3H were then infected in triplicate at low MOI (at MOI = 0.01 and 0.05) with a replication-competent HIV-1 with a deletion that spans the Vif open reading frame (HIV-1ΔVif). Virus production was monitored over time by collecting supernatant and measuring RT activity using the SG-PERT assay to measure RT in virions in the supernatants (Fig 5B for MOI = 0.01 and S2 Fig for MOI = 0.05) . In Jurkat cells expressing the empty vector, HIV-1ΔVif grew exponentially until peaking at day 10 at both MOIs of infection (Fig 5B and S2 Fig, panel A, “No A3”, gray line). There was no initial restriction of HIV-1ΔVif in A3G-expressing cells, as expected given the requirement of packaging before HIV-1 restriction. However, at later time points, HIV-1ΔVif growth was inhibited by the A3G-expressing cells, as the RT levels did not further increase and remained at levels much lower than in Jurkat cells without A3 proteins. Remarkably similar to cells expressing A3G, the cells expressing A3C-A3H also efficiently controlled infection of HIV-1ΔVif after day 5 of infection.
We used the area under the curve (AUC) as a metric to statistically compare virus spreading between cell lines (Fig 5B). We determined the AUC for each of the three biological replicate infections and report the mean and standard error (Fig 5B). We found that the AUC for A3G and A3C-A3H infections were approximately 3-4-fold less than the no A3 Jurkat cells, indicating significant HIV-1 restriction (p = 0.031 and 0.046, respectively, one-way ANOVA and the post hoc Tukey’s multiple comparisons test). In contrast, there was no statistical difference between the AUC of the A3G- and A3C-A3H-expressing cells. Thus, these results show that A3C-A3H stably expressed in T cells is as effective as A3G in controlling HIV-1 infection in the absence of Vif.
To determine whether the HIV-1ΔVif inhibition in T cells was due to hypermutation or an alternative mechanism, as determined in the single-cycle infectivity assays (Fig 3), we harvested genomic DNA from infected cells at day 14 (Fig 5B) and deep sequenced a region of pol to evaluate if integrated proviruses had signatures of A3 mediated hypermutation (Fig 5C). As in Fig 3, we used a plasmid control to determine background mutations from PCR and Illumina sequencing errors (Fig 5C). As these samples were collected at 14 days post-infection, the no A3 genomic DNA sample contains additional G-to-A mutations compared to the single cycle infectivity assay results in Fig 3A because of the errors made from reverse transcription after multiple rounds of infection  (and possibly also due to low level basal A3 proteins in Jurkat cells). In the genomic DNA of the cells expressing A3G, we find that there is an increase in the frequency of G-to-A mutations, with approximately 20% of the reads having 10 or more G-to-A mutations. Consistent with our single-cycle infection data, in the genomic DNA of cells expressing A3C-A3H, we found that there were very few additional G-to-A mutations when compared to the no A3 cells. In fact, the no A3 and A3C-A3H frequency graphs look nearly identical. These data show that A3C-A3H stably expressed in T cells can inhibit a Vif-deficient HIV-1 as well as A3G, but that the mechanisms of increased inhibition are largely independent of hypermutation.
We also tested if Vif could overcome the antiviral activity A3C-A3H in this system by infecting each of the three cells lines with wtHIV-1 infection (i.e. HIV-1 that encodes the Vif protein). We found the wtHIV grew to approximately similar levels regardless of whether or not any A3 was expressed in these cells (Figs 5D and S2). We also collected cell lysates from day 14 in the HIV-1ΔVif and wtHIV-1 infection and performed a western blot to examine the intracellular expression levels of A3G and A3C-A3H. We found that when we compared the intracellular expression in each of 3 biological replicates of the cell lines that were infected with wtHIV-1 to HIV-1ΔVif, the A3 expression was lower in the presence of HIV-1 Vif, consistent with the Vif-mediated degradation of A3 (Fig 5E). Together, these data show that A3C-A3H is just as potent of a restriction factor as A3G in the absence of HIV-1 Vif; however, it is nonetheless antagonized by Vif and targeted for degradation.
Here we combined two single domain A3 proteins, A3C and A3H that encode A3Z2 and A3Z3 domains, respectively, into a single molecule to test the hypothesis that there is novel antiviral potential in the human A3 locus. We found that these A3C/A3H double domains can create super restriction factors with antiviral potency that is at least as potent as A3G both in single-cycle assays and in spreading infections of T cells. The ability of the A3C/A3H synthetic double domain proteins to inhibit reverse transcription after viral infection of the target cells, rather than an increased ability to induce hypermutation, correlates with their increased ability to inhibit HIV-1 (Fig 3). Thus, it is possible to create novel combinations of A3 domains with just as potent antiviral activity as A3G that enhance a non-enzymatic mechanism of action.
Why are A3C/A3H double domains so potently antiviral?
Not all novel double domain A3 combinations gain such potent antiviral activity. We previously showed that linking together two A3H haplotypes to form an A3H-A3H double domain does not increase antiviral activity [42,43] and linking two A3C domains together to form A3C-A3C leads to modest increases in antiviral activity (Fig 1 and ). However, here we created heterologous double domains using A3C and A3H and show that A3C/A3H double domains are over 100-fold more potent than A3C-A3C (Fig 1B). One possibility is that combining two different evolutionary distinct domains, such as with A3G being a combination of Z2 and Z1 domains, creates a more potent restriction factor because each domain has specialized contributions to substrate specificity, binding affinity, deamination activity, and/or packaging into virions, allowing for independent and additive activities . For example, both A3F and A3G primarily rely on only the C-terminal domains for catalytic activity, allowing for the N-terminal domain to perform other aspects involved in restriction [44–46]. The full-length human A3G structure provides insights about how the two domains interact to form a channel between the N-terminal and C-terminal domain to form additional affinity to ssDNA [47,48]. We speculate that having two different Z domains in a double deaminase domain protein could provide fitness advantages to sub-specialization of each domain.
A3C/A3H double domains, unlike their single domain counterparts or even A3G, restrict HIV-1 primarily through a deaminase-independent mechanism (Fig 3A and 3B). Our data is consistent with the model that these double domains have gained an ability to interfere with the reverse transcription process, leading to fewer intact HIV-1 integration products (Fig 3C). The deaminase-independent mechanism of inhibition of HIV-1 could result from cumulative delays in reverse transcriptase products because of binding the template RNA, binding to negative-strand DNA, and/or binding to reverse transcriptase, thereby preventing proviral DNA synthesis [29–31,49–51]. A3F and A3G have been shown to interact with reverse transcriptase to negatively regulate its activity [28–31,51]. Additionally, dimerization of A3G has been shown to slow the dissociation of A3G from ssDNA and reduce its scanning ability . A3H requires a double-stranded RNA to make functional dimers [33–35], but here we show that the binding affinity of the A3C-A3H double domain to the HIV-1 5’UTR RNA is over 10-fold greater than A3Hhap II and over 200-fold greater than A3G (Fig 4). Thus, these data are consistent with the hypothesis that increased packaging as well as increased affinity for RNA compared to their single domain counterparts is the mechanism by which these super restriction factors block reverse transcriptase from synthesizing full-length proviral DNA.
The major factor mediating interactions between A3s and nucleic acids is the electrostatic interactions between positively charged amino acids and the negatively charged nucleic acid phosphate backbone. For A3Hhap II, the overall charge of the amino acid sequence at pH 7.5 is +6.3 (http://protcalc.sourceforge.net/). In contrast, A3C has an overall negative charge of -0.7. We hypothesize that the positive charge of the A3Hhap II would increase the interaction time of A3C with RNA, similar to what has been shown for the two A3G domains on RNA and ssDNA [53,54]. However, the two domains of A3G are more different in charge with the N-terminal domain being +9.9 and the C-terminal domain being -6.3 at pH 7.5. This correlates with weaker RNA binding for A3G in comparison to A3C-A3H (Fig 4), which has less disparity between the charge of the two domains.
Furthermore, RNA binding has been implicated for proper subcellular localization of A3F, A3G, and A3H [33,34,55–61]. Treatment with RNase A can disrupt interactions between A3s and cellular proteins, hinting at RNA playing an important role in regulating A3 activities [33–35,62]. A3Hhap I has been reported to have reduced RNA binding  and could explain why A3C/A3Hhap I double domains are less active compared to A3C/A3Hhap II double domains (Fig 1B). Additionally, as there is a gain in the protein expression level of A3Hhap I in the A3C/A3Hhap I double domains (Fig 1B), this phenotype could be due to an increase in RNA interactions leading to the gain in stability of A3Hhap I chimeras.
A3C-A3H inhibits HIV-1ΔVif, but not wtHIV-1 in a spreading infection in T cells
It has been argued that transient expression of A3 proteins in 293T cells exaggerates their antiviral activity and that stable expression in T cells is a better predictor of their true antiviral activity . Here, we tested cells expressing A3C-A3H against wtHIV-1 and HIV-1ΔVif in spreading infections in Jurkat cells that stably expressed A3C-A3H and found that these experiments recapitulated the single-cycle infections, demonstrating that A3C-A3H is as potent as A3G in inhibiting HIV-1ΔVif, but though a novel, non-catalytic mechanism (Figs 1 and 3). We previously found that an A3C-A3C synthetic tandem domain protein was relatively resistant to Vif antagonism . However, in contrast to the HIV-1ΔVif infection, we found that wtHIV-1 (i.e. HIV-1 that expressed Vif) was able to replicate in A3C-A3H-expressing cells to similar levels to the A3G- and no A3-expressing cells (Fig 5D). Thus, despite A3C-A3H being a novel target for HIV-1 Vif, this data shows that HIV-1 Vif has the potential to target novel A3 double domains. Vif uses three interfaces to bind to antiviral A3s: one for A3G, another for A3H, and a third for A3C/A3D/A3F . In the double domain A3C/A3H combinations, either the A3C or the A3H determinants for Vif degradation must still be surface-exposed. Future experiments will determine if we can additionally select for potent super restrictor A3 combinations that are resistant to Vif.
Why has a A3Z3 rarely been used in a double domain A3?
Despite the potent antiviral activity of A3C/A3H double domains, no primate genome currently contains a functional double domain A3 containing a Z3 domain [8,9,12]. Interestingly, no mammalian groups have a detectable Z3 duplication except for in Carnivora, in which the A3Z3 duplication has been almost entirely pseudogenized  (although felines make a splice RNA variant that encodes a readthrough product of a Z2-Z3 fusion protein ). These results suggest that Z3 domains may have alternative, harmful deaminase targets like cellular genomic DNA, precluding their inclusion in highly potent double domain A3s. A3B and A3Hhap I, A3s with more nuclear localization, have been implicated in contributing to cancer, suggesting that they could be detrimental to the host [64,65]. However, we were able to create cell lines that express A3C-A3H (Fig 5) with no obvious growth defects, although this does not rule out long-term or more subtle growth defects.
Another hypothesis is that generation of a cytidine deaminase-independent mechanisms of inhibition is inherently less optimal than an antiviral activity based on hypermutation, and that nature has selected against those A3 combinations of domains that do not favor enzymatic activity rather than inhibition of reverse transcription. Since A3-mediated hypermutation leads to broad and permanent inactivation of the viral genome, this mechanism of inhibition might have been selected. However, because cells expressing A3C-A3H where able to inhibit viral replication to similar levels as A3G, this possibility seems less likely. Nevertheless, by making novel tandem domain proteins not found in primate genomes, we have learned that more potent antiviral activity can be achieved with deaminase-independent mechanisms, such as increase packaging of A3s into budding virions, increased RNA binding, and inhibition of reverse transcription. Thus, our data suggest that there is an untapped mechanism of potent antiviral activity within the A3 locus that could block reverse transcription directly rather than act through hypermutation.
Materials and methods
The plasmids were created using the A3C sequence  and A3Hhap I  and were designed based on similar alignments as A3D and A3F, incorporating the naturally found short linker amino acid sequence between both domains Arg-Asn-Pro (RNP) in A3D and A3F as previously described . Hybrid A3 constructs generated via gene synthesis (Integrated DNA Technologies, IDT) for both A3C-A3Hhap I and A3Hhap I-A3C. To create all mutations and the A3Hhap II variants of these A3C/A3H double domains, Site-Directed Mutagenesis using the QuikChange II XL kit (Agilent, #200522–5) was performed and the mutations were confirmed by sanger sequencing. To convert the A3Hhap I into A3Hhap II, the following mutations were made: G105R and K121D, using Site Directed Mutagenesis . Wild-type A3Hhap II behaves the same as A3Hhap I R105 D121 . To create the active site knockout mutants, mutations were made in both the N- and C- terminal domains, E68A and E254A, for a catalytically inactive variant. All constructs have a C-terminal 3XFLAG epitope tag and were cloned into the pcDNA4/TO vector backbone (Thermo Fisher, #V102020) using restriction sites at EcoRI/XhoI.
Cell culture and transfections
Jurkat (ATCC TIB-152) and SUPT1 (ATCC CRL-1942) cells were maintained in RPMI Medium (Gibco, #11875093), with 10% Fetal Bovine Serum (GE Healthcare, #SH30910.03), 1% Penicillin Streptomycin (Gibco, #15140122), and 1% HEPES at 37°C, referred to as RPMI complete. HEK293T cells (ATCC CRL-3216) were maintained in Dulbecco’s modified Eagle’s medium (Gibco, #11965092) with 10% Fetal Bovine Serum (GE Healthcare, #SH30910.03), and 1% Penicillin Streptomycin (Gibco, #15140122) at 37°C. The plasmids were transfected into the cells using TransIT-LT1 transfection reagent (Mirus, MIR2304) at a ratio of 3:1 mirus:plasmid.
Single-cycle infectivity assays
Single-cycle infectivity assays were previously described in [20,22]. In short, 293T cells were seeded in 6-well plates at a density of 1.5x105 cells per mL. 24 hours later, the cells were transfected with 600ng of HIV-1ΔEnvΔVif provirus (LAI strain), 100ng of L-VSV-G, and 100ng of A3 plasmid for all single-cycle infectivity assay unless otherwise noted. 72 hours post transfection, virus was collected and filtered through a 0.3 micron syringe filter. Virus titers were determined using a SG-PERT assay as described in . 2x104 SUPT1 cells per well were seeded into a 96 well plate supplemented with 20μg/mL of DEAE-dextran. All infections were done in technical triplicate. 72 hours post infection, the cells were lysed with a 1:1 ratio of virus to Bright-Glo luciferase assay media (Promega, #E2610) and the contents were analyzed on a luminometer (LUMISTAR Omega, BMG Labtech). Values were normalized to the no A3 samples and graphed on Prism software.
Cells were lysed with NP-40 buffer (0.2M Sodium Chloride, 0.05M Tris pH7.4, 0.5M NP-40 Alternative, 0.001M DTT, Protease Inhibitor Cocktail (Roche Complete Mini, EDTA-free tablets, 11836170001) 72 hours post transfection. The cell lysates were centrifuged at 4°C at 1,000 rpm for 10 minutes to remove the nuclei pellet. The supernatant was transferred to a new set of a tubes and spun down at 13,000 rpm for 10 minutes at 4°C to remove the remaining debris. The supernatant was transferred to a new set of tubes and lysed in 4X loading dye (Invitrogen, #NP0007) and boiled at 95°C for 10 minutes. The boiled samples were resolved on a 4–12% Bis-Tris gel, transferred to a nitrocellulose membrane (Bio-Rad, 1620115), and blotted with antibodies to detect protein levels. Anti-FLAG (Sigma, F3164), and anti-p24gag (NIH-ARP, 3537) antibodies were used at 1:10,000, and Actin (Sigma, A2066), StarBright Blue 520 Goat Anti-Rabbit IgG (Bio-Rad, 12005869) and StarBright Blue 700 Goat Anti-Mouse IgG (Bio-Rad, 12005866) were used at a ratio of 1:5,000.
Quantification of late reverse transcription products
Quantification of late reverse transcription products was previously described in [22,66]. In short, cells were harvested 19 hours post-infection and unintegrated cDNA was collected using the Qiagen mini-prep kit (QIAprep Spin Miniprep Kit, # 27106). Samples were concentrated using the Zymo DNA Clean and Concentrator-25 kit (Zymo, D4033). HIV cDNA was amplified with TaqMan gene expression master mix (Applied Biosystems, 4369016), J1 FWD (late RT F)—ACAAGCTAGTACCAGTTGAGCCAGATAAG, J2 REV (late RT R) GCCGTG CGCGCTTCAGCAAGC, and LRT-P (late RT probe)—6-carboxyfluorescein (FAM)-CAGTGGCGCCCGAACAG GGA-6-carboxytetramethylrhodamine (TAMRA) [67,68]. Data were acquired on an ABI QuantStudio5 real-time (qPCR) machine and analyzed on Prism software.
A3 mediated hypermutation assay
The A3 mediated hypermutation assay was previously described in . In short, SUPT1 cells were infected with Benzonase-treated HIV-1ΔVifΔEnv virus pseudotyped with VSVg and the designated A3. 19 hours later, unintegrated viral cDNA was isolated using a Qiagen miniprep kit (QIAprep Spin miniprep kit; catalog no. 27106). To determine A3-mediated mutations, we used a barcoded Illumina deep-sequencing approach as previously described [22,69]. Samples were amplified, quantified, pooled, purified via gel electrophoresis, and sequenced on an Illumina MiSeq sequencer, using 2x250 paired-end reads.
The dms_tools2 software packaged was used to align sequencing reads and build consensus sequences for each uniquely tagged DNA molecule . Error-corrected reads were compared to the target sequence to determine the number, identity, and surrounding nucleotides of all substitutions in each read. Reads with high numbers of substitutions (>10% of non-G nucleotides) at the junction of the two paired-end reads were removed from the analysis as these substitutions were most often found to be alignment artifacts. Since A3s are known to cause G-to-A substitutions, we subsampled our data to specifically at G-to-A substitutions. The data is shown as the frequency of reads in each sample with a given number of G-to-A mutations (0, 1, 2, etc., up to 9 and then 10+).
Jurkat T cell lines stably expressing A3 proteins
In order to create constitutively expressed A3 cell lines, the Sleeping Beauty transposase system  was adapted to electroporate Jurkat cells using the Lonza SE Cell Line kit (Lonza, V4SC-1960). The pSBbi-RP plasmid was a gift from Eric Kowarz (Addgene plasmid #60513) . A3G-3XFLAG was cloned into the pSBbi-RP vector using the NcoI/XbaI restriction sites. A3C-A3Hhap II-3XFLAG was cloned into the pSBbi-RP vector using the EcoRV/XbaI restriction sites. Using the Lonza 4D-Nucleofactor (program ‘Jurkat E6.1(NEW)’ and pulse code ‘CK116’), Jurkat cells were electroporated with the pSBbi-RP-A3 and pCMV(CAT)T7-SB100 (gift from Zsuzsanna Izsvak, Addgene plasmid #34879) . Post electroporation, cells were recovered in RPMI and 24 hours later, transferred into RPMI supplemented with 0.4μg/mL puromycin for selection. To further ensure that only electroporated cells survived, cells were flow sorted for dTomato positive cells and maintained in RPMI media supplemented with 0.2μg/mL puromycin (Sigma, #P8833) selection. Additionally, cells were sorted for similar CD4 levels, using APC anti-human CD4 (PharMingen, #555349), based on the CD4 levels of the A3C-A3Hhap II expressing cells.
wtHIV-1 (LAI strain) and HIV-1ΔVif virus stocks were created by transfecting HEK293T cells with 1μg of viral plasmid per well in a 6 well plate. The virus was titered on the Jurkat stable cell lines, via flow cytometry staining for p24-FITC (Beckman Coulter, 6604665) positive cells. The stable Jurkat cell lines were then infected at an MOI of 0.01 and 0.05. Virus and 20μg/mL DEAE-Dextran in RPMI were added to cells, spinoculated for 30 min at 1100xg, and post infection, fresh RPMI media was added to the cells. The spreading infection was drawn out for 14 days and performed in triplicate. The cells were closely monitored, and supernatant samples were taken every 2–3 days. Reverse transcriptase was quantified in the collected viral supernatant using a SG-PERT assay . Cell lysates were collected on day 14 and split into two samples. These cell lysates were run on a western blot to check for A3 protein expression and used to harvest gDNA (QIAamp DNA Blood mini kit, #51104) for the A3 mediated hypermutation assay.
Steady-state rotational anisotropy
For generation of RNA in vitro, the HIV 5′-UTR (nucleotides 1–497) was cloned into pSP72 vector (Promega) using BglII and EcoRI sites under the control of T7 promoter. All constructed plasmids were verified by DNA sequencing. Primers were obtained from IDT and are reported in Feng et al . Fluorescently labeled RNA was produced by transcribing pSP72 DNA cut with EcoRI in vitro using T7 RNA polymerase with a nucleotide mixture containing fluorescein-12-UTP (Roche Applied Science). Steady-state rotational anisotropy reactions (60 μL) were conducted in buffer containing 50 mM Tris, pH 7.5, 40 mM KCl, 10 mM MgCl2, and 1 mM DTT and contained 10 nM fluorescein-labeled 5’UTR RNA and increasing amounts of A3 (A3Hhap II, 0.1–61 nM; A3C-A3Hhap II, 0.0045–6.040 nM; and A3G, 0.36202 nM). A QuantaMaster QM-4 spectrofluorometer (Photon Technology International) with a dual emission channel was used to collect data and calculate anisotropy. Measurements were performed at 21°C. Samples were excited with vertically polarized light at 495 nm (6-nm band pass), and vertical and horizontal emissions were measured at 520 nm (6-nm band pass). The Kd was obtained by fitting to a hyperbolic decay curve equation using SigmaPlot version 11.2 software.
S1 Fig. Annotated A3C-A3HhapI and A3HhapI-A3C sequences.
Full length sequences used to construct the A3C-A3H and A3H-A3C double deaminase domains. The “RNP” amino acid sequence (Arginine-Asparagine-Proline) that links the two deaminase domains together is highlighted in yellow. The essential glutamic acid that is necessary for deaminase activity is in red text. The A3H human polymorphic sites are shown in blue text.
S2 Fig. A3C/A3H expressing cells inhibit viral replication at an MOI = 0.05.
Spreading infection kinetics of a replication-competent HIV-1 with a deletion that spans the Vif open reading frame (called HIV-1ΔVif) (A) or wtHIV-1 (LAI isolate) (B). The Jurkat cells expressing no A3 (circle, grey line), A3G (square, orange line), or A3C-A3Hhap II (celled A3C-A3H, triangle, blue line) were infected at a low MOI (MOI = 0.05) in triplicates. Virus production was monitored over time by collecting supernatant and measuring RT activity (mU/mL) using a SG-PERT assay. Error bars represent the standard error across the 3 biological replicates.
We thank Molly Ohainle, Jeannette Tenthorey, and Nicholas Chesarino for their helpful feedback on this manuscript, James Dargan for his assistance with the A3-mediated hypermutation code, and the Fred Hutchinson Shared Resources Genomic Core.
- 1. Daugherty MD, Malik HS. Rules of engagement: Molecular insights from host-virus arms races. Annu Rev Genet. 2012;46: 677–700. pmid:23145935
- 2. Duggal NK, Emerman M. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol. 2012;12: 687–695. pmid:22976433
- 3. Schilling M, Bulli L, Weigang S, Graf L, Naumann S, Patzina C, et al. Human MxB Protein Is a Pan-herpesvirus Restriction Factor. J Virol. 2018;92: 1–11. pmid:29950411
- 4. Verhelst J, Hulpiau P, Saelens X. Mx Proteins: Antiviral Gatekeepers That Restrain the Uninvited. Microbiol Mol Biol Rev. 2013;77: 551–566. pmid:24296571
- 5. Liu Z, Pan Q, Ding S, Qian J, Xu F, Zhou J, et al. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe. 2013;14: 398–410. pmid:24055605
- 6. Goujon C, Moncorgé O, Bauby H, Doyle T, Ward CC, Schaller T, et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature. 2013;502: 559–562. pmid:24048477
- 7. Tareen SU, Sawyer SL, Malik HS, Emerman M. An expanded clade of rodent Trim5 genes. Virology. 2009;385: 473–483. pmid:19147168
- 8. Münk C, Willemsen A, Bravo IG. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol Biol. 2012;12: 71. pmid:22640020
- 9. Ito J, Gifford RJ, Sato K. Retroviruses drive the rapid evolution of mammalian APOBEC3 genes. Proc Natl Acad Sci U S A. 2020;117: 610–618. pmid:31843890
- 10. LaRue RS, Andresdottir V, Blanchard Y, Conticello SG, Derse D, Emerman M, et al. Guidelines for Naming Nonprimate APOBEC3 Genes and Proteins. J Virol. 2008;83: 494–497. pmid:18987154
- 11. Yang L, Emerman M, Malik HS, McLaughlin RN Jnr. Retrocopying expands the functional repertoire of APOBEC3 antiviral proteins in primates. Elife. 2020;9: 1–18. pmid:32479260
- 12. Uriu K, Kosugi Y, Suzuki N, Ito J, Sato K. Elucidation of the Complicated Scenario of Primate APOBEC3 Gene Evolution. J Virol. 2021;95. pmid:33789992
- 13. Sawyer SL, Emerman M, Malik HS. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2004;2. pmid:15269786
- 14. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, et al. Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity To Restrict Vif-Deficient HIV-1. J Virol. 2011;85: 11220–11234. pmid:21835787
- 15. Wittkopp CJ, Adolph MB, Wu LI, Chelico L, Emerman M. A Single Nucleotide Polymorphism in Human APOBEC3C Enhances Restriction of Lentiviruses. PLoS Pathog. 2016;12: 1–24. pmid:27732658
- 16. Ebrahimi D, Richards CM, Carpenter MA, Wang J, Ikeda T, Becker JT, et al. Genetic and mechanistic basis for APOBEC3H alternative splicing, retrovirus restriction, and counteraction by HIV-1 protease. Nat Commun. 2018;9: 1–11.
- 17. Ohainle M, Kerns J a, Malik HS, Emerman M. Adaptive Evolution and Antiviral Activity of the Conserved Mammalian Cytidine Deaminase APOBEC3H. J Virol. 2006;80: 3853–3862. pmid:16571802
- 18. Ohainle M, Kerns JA, Li MMH, Malik HS, Emerman M. Antiretroelement Activity of APOBEC3H Was Lost Twice in Recent Human Evolution. Cell Host Microbe. 2008;4: 249–259. pmid:18779051
- 19. Refsland EW, Hultquist JF, Luengas EM, Ikeda T, Shaban NM, Law EK, et al. Natural Polymorphisms in Human APOBEC3H and HIV-1 Vif Combine in Primary T Lymphocytes to Affect Viral G-to-A Mutation Levels and Infectivity. PLoS Genet. 2014;10. pmid:25411794
- 20. Li MMH, Wu LI, Emerman M. The Range of Human APOBEC3H Sensitivity to Lentiviral Vif Proteins. J Virol. 2010;84: 88–95. pmid:19828612
- 21. Colón-Thillet R, Hsieh E, Graf L, McLaughlin RN, Young JM, Kochs G, et al. Combinatorial mutagenesis of rapidly evolving residues yields super-restrictor antiviral proteins. PLOS Biol. 2019;17: e3000181. pmid:31574080
- 22. McDonnell MM, Crawford KHD, Dingens AS, Bloom JD, Emerman M. APOBEC3C Tandem Domain Proteins Create Super Restriction Factors Against HIV-1. MBio. 2020;11: 1–18. pmid:32345636
- 23. Tenthorey JL, Young C, Sodeinde A, Emerman M, Malik HS. Mutational resilience of antiviral restriction favors primate TRIM5α in host-virus evolutionary arms races. Elife. 2020;9: 1–36. pmid:32930662
- 24. Zielonka J, Marino D, Hofmann H, Yuhki N, Lochelt M, Munk C. Vif of Feline Immunodeficiency Virus from Domestic Cats Protects against APOBEC3 Restriction Factors from Many Felids. J Virol. 2010;84: 7312–7324. pmid:20444897
- 25. Li J, Chen Y, Li M, Carpenter MA, McDougle RM, Luengas EM, et al. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells. J Mol Biol. 2014;426: 1296–1307. pmid:24361275
- 26. Harris RS, Dudley JP. APOBECs and virus restriction. Virology. 2015;479–480: 131–145. pmid:25818029
- 27. Gillick K, Pollpeter D, Phalora P, Kim E-Y, Wolinsky SM, Malim MH. Suppression of HIV-1 Infection by APOBEC3 Proteins in Primary Human CD4 + T Cells Is Associated with Inhibition of Processive Reverse Transcription as Well as Excessive Cytidine Deamination. J Virol. 2013;87: 1508–1517. pmid:23152537
- 28. Newman ENC, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, et al. Antiviral Function of APOBEC3G Can Be Dissociated from Cytidine Deaminase Activity. Curr Biol. 2005;15: 166–170. pmid:15668174
- 29. Pollpeter D, Parsons M, Sobala AE, Coxhead S, Lang RD, Bruns AM, et al. Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G. Nat Microbiol. 2018;3. pmid:29158605
- 30. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 2008;4: 13–20. pmid:19057663
- 31. Iwatani Y, Chan DSB, Wang F, Maynard KS, Sugiura W, Gronenborn AM, et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 2007;35: 7096–7108. pmid:17942420
- 32. Feng Y, Wong L, Morse M, Rouzina I, Williams MC, Chelico L. RNA-Mediated Dimerization of the Human Deoxycytidine Deaminase APOBEC3H Influences Enzyme Activity and Interaction with Nucleic Acids. J Mol Biol. 2018;430: 4891–4907. pmid:30414963
- 33. Ito F, Yang H, Xiao X, Li S, Wolfe A, Zirkle B. Understanding the Structure, Multimerization, Subcellular Localization and mC Selectivity of a Genomic Mutator and Anti-HIV Factor APOBEC3H. Sci Rep. 2018; 1–15.
- 34. Shaban NM, Shi K, Lauer KV., Carpenter MA, Richards CM, Salamango D, et al. The Antiviral and Cancer Genomic DNA Deaminase APOBEC3H Is Regulated by an RNA-Mediated Dimerization Mechanism. Mol Cell. 2018;69: 75–86.e9. pmid:29290613
- 35. Bohn JA, Thummar K, York A, Raymond A, Brown WC, Bieniasz PD, et al. APOBEC3H structure reveals an unusual mechanism of interaction with duplex RNA. Nat Commun. 2017;8: 2–10.
- 36. Baig TT, Feng Y, Chelico L. Determinants of Efficient Degradation of APOBEC3 Restriction Factors by HIV-1 Vif. J Virol. 2014;88: 14380–14395. pmid:25275135
- 37. Jameson DM, Ross JA. Fluorescence Polarization/Anisotropy in Diagnostics and Imaging. Chem Rev. 2010;110: 2685–2708. pmid:20232898
- 38. Wang T, Zhang W, Tian C, Liu B, Yu Y, Ding L, et al. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. Virology. 2008;377: 71–79. pmid:18495196
- 39. Ivics ZN, Hackett PB, Plasterk RH, Izsvá Z. Molecular Reconstruction of Sleeping Beauty, a Tc1-like Transposon from Fish, and Its Transposition in Human Cells. Cell. 1997;91: 501–510. pmid:9390559
- 40. Vermeire J, Naessens E, Vanderstraeten H, Landi A, Iannucci V, van Nuffel A, et al. Quantification of Reverse Transcriptase Activity by Real-Time PCR as a Fast and Accurate Method for Titration of HIV, Lenti- and Retroviral Vectors. PLoS One. 2012;7. pmid:23227216
- 41. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995;69: 5087–5094. pmid:7541846
- 42. Li MMH, Emerman M. Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity. J Virol. 2011;85: 8197–8207. pmid:21653666
- 43. Chesarino NM, Emerman M. Polymorphisms in human APOBEC3H differentially regulate ubiquitination and antiviral activity. Viruses. 2020;12. pmid:32235597
- 44. Navarro F, Bollman B, Chen H, König R, Yu Q, Chiles K, et al. Complementary function of the two catalytic domains of APOBEC3G. Virology. 2005;333: 374–386. pmid:15721369
- 45. Hache G, Liddament MT, Harris RS. The Retroviral Hypermutation Specificity of APOBEC3F and APOBEC3G Is Governed by the C-terminal DNA Cytosine Deaminase Domain. J Biol Chem. 2005;280: 10920–10924. pmid:15647250
- 46. Feng Y, Chelico L. Intensity of Deoxycytidine Deamination of HIV-1 Proviral DNA by the Retroviral Restriction Factor APOBEC3G Is Mediated by the Noncatalytic Domain. J Biol Chem. 2011;286: 11415–11426. pmid:21300806
- 47. Maiti A, Myint W, Delviks-Frankenberry KA, Hou S, Kanai T, Balachandran V, et al. Crystal Structure of a Soluble APOBEC3G Variant Suggests ssDNA to Bind in a Channel that Extends between the Two Domains. J Mol Biol. 2020;432: 6042–6060. pmid:33098858
- 48. Yang H, Ito F, Wolfe AD, Li S, Mohammadzadeh N, Love RP, et al. Understanding the structural basis of HIV-1 restriction by the full length double-domain APOBEC3G. Nat Commun. 2020;11. pmid:32005813
- 49. Adolph MB, Webb J, Chelico L. Retroviral Restriction Factor APOBEC3G Delays the Initiation of DNA Synthesis by HIV-1 Reverse Transcriptase. PLoS One. 2013;8. pmid:23717565
- 50. Adolph MB, Ara A, Chelico L. APOBEC3 Host Restriction Factors of HIV-1 Can Change the Template Switching Frequency of Reverse Transcriptase. J Mol Biol. 2019;431: 1339–1352. pmid:30797859
- 51. Holmes RK, Koning FA, Bishop KN, Malim MH. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation: Comparisons with APOBEC3G. J Biol Chem. 2007;282: 2587–2595. pmid:17121840
- 52. Morse M, Huo R, Feng Y, Rouzina I, Chelico L, Williams MC. Dimerization regulates both deaminase-dependent and deaminase-independent HIV-1 restriction by APOBEC3G. Nat Commun. 2017;8: 597. pmid:28928403
- 53. Morse M, Naufer MN, Feng Y, Chelico L, Rouzina I, Williams MC. HIV restriction factor APOBEC3G binds in multiple steps and conformations to search and deaminate single-stranded DNA. Elife. 2019;8: 1–23. pmid:31850845
- 54. Chelico L, Prochnow C, Erie DA, Chen XS, Goodman MF. Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J Biol Chem. 2010;285: 16195–16205. pmid:20212048
- 55. Gallois-montbrun S, Holmes RK, Swanson CM, Ferna M, Byers HL, Ward MA, et al. Comparison of Cellular Ribonucleoprotein Complexes Associated with the APOBEC3F and APOBEC3G Antiviral Proteins. J Virol. 2008;82: 5636–5642. pmid:18367521
- 56. Izumi T, Burdick R, Shigemi M, Plisov S, Hu W-S, Pathak VK. Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity. J Virol. 2013;87: 11047–62. pmid:23926332
- 57. Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J Biol Chem. 2006;281: 29105–29119. pmid:16887808
- 58. Phalora PK, Sherer NM, Wolinsky SM, Swanson CM, Malim MH. HIV-1 Replication and APOBEC3 Antiviral Activity Are Not regulated by P bodies. J Virol. 2012;86: 11712–11724. pmid:22915799
- 59. Wichroski MJ, Robb GB, Rana TM. Human Retroviral Host Restriction Factors APOBEC3G and APOBEC3F Localize to mRNA Processing Bodies. PLOS Pathog. 2006;2: 374–383. pmid:16699599
- 60. Stenglein MD, Matsuo H, Harris RS. Two Regions within the Amino-Terminal Half of APOBEC3G Cooperate To Determine Cytoplasmic Localization. J Virol. 2008;82: 9591–9599. pmid:18667511
- 61. Salamango DJ, Becker JT, Mccann JL, Cheng AZ, Demir Ö. APOBEC3H Subcellular Localization Determinants Define Zipcode for Targeting HIV-1 for Restriction. Mol Cell Biol. 2018;38: 1–17. pmid:30224517
- 62. Zhen A, Du J, Zhou X, Xiong Y, Yu XF. Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities. PLoS One. 2012;7: 1–10. pmid:22859935
- 63. Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, Pathak VK. Multiple APOBEC3 restriction factors for HIV-1 and one vif to rule them all. J Mol Biol. 2014;426: 1220–1245. pmid:24189052
- 64. Starrett GJ, Luengas EM, McCann JL, Ebrahimi D, Temiz NA, Love RP, et al. The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis. Nat Commun. 2016;7: 12918. pmid:27650891
- 65. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 2013;45: 977–983. pmid:23852168
- 66. Ohainle M, Kim K, Komurlu Keceli S, Felton A, Campbell E, Luban J, et al. TRIM34 restricts HIV-1 and SIV capsids in a TRIM5α-dependent manner. PLOS Pathog. 2020;16: e1008507. pmid:32282853
- 67. De Iaco A, Luban J. Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus. Retrovirology. 2011;8: 98. pmid:22145813
- 68. Butler SL, Hansen MST, Bushman FD. A quantitative assay for HIV DNA integration in vivo. Nat Med. 2001;7: 631–634. pmid:11329067
- 69. Doud MB, Bloom JD. Accurate Measurement of the Effects of All Amino-Acid Mutations on Influenza Hemagglutinin. Viruses. 2016;8. pmid:27271655
- 70. Bloom JD. Software for the analysis and visualization of deep mutational scanning data. BMC Bioinformatics. 2015;16: 1–13.
- 71. Kowarz E, Löscher D, Marschalek R. Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines. Biotechnol J. 2015;10: 647–653. pmid:25650551
- 72. Mátés L, Chuah MKL, Belay E, Jerchow B, Manoj N, Acosta-Sanchez A, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet. 2009;41: 753–761. pmid:19412179
- 73. Feng Y, Love RP, Ara A, Baig TT, Adolph MB, Chelico L. Natural polymorphisms and Oligomerization of Human APOBEC3H contribute to single-stranded DNA scanning ability. J Biol Chem. 2015;290: 27188–27203. pmid:26396192